Elizabeth Trice Loggers, MD, PhD
Group Health Physician, Oncology
Research interests and experience
- End-of-life care: quality of care; communication; racial disparities
- Cancer control: quality of life; health outcomes; end-of-life care; participation in clinical trials; Hispanic acculturation and cancer outcomes; geriatrics; patient/provider interaction
- Health services & economics: primary care delivery and cancer outcomes; intensity and cost of care; comparative effectiveness analyses
- Rare cancers: treatment variability and outcomes; end-of-life care
Elizabeth Trice Loggers joined Group Health Research Institute in 2009 after completing a fellowship in the Department of Medical Oncology at the Dana-Farber Cancer Institute (DFCI). Her research while at the Center for Psycho-oncology and Palliative Care Research at DFCI focused primarily on communication and end-of-life care for advanced cancer patients, with an emphasis on racial and ethnic differences. Her position as assistant investigator is a joint appointment with the Clinical Research Division of Fred Hutchinson Cancer Research Center. Dr. Loggers maintains a part-time clinical practice at Seattle Cancer Care Alliance where she specializes in the treatment of individuals with sarcoma (i.e., cancers of the bone, muscles, nerves, or vessels) and is the Medical Director for Palliative Care.
Loggers ET, Fishman PA, Peterson D, O'Keeffe-Rosetti M, Greenberg C, Hornbrook MC, Kushi LH, Lowry S, Ramaprasan A, Wagner EH, Weeks JC, Ritzwoller DP. Advanced imaging among health maintenance organization enrollees with cancer. J Oncol Pract. 2014 May 20. pii: JOP.2013.001258 [Epub ahead of print]. PubMed
Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Aiello Bowles EJ, Loggers ET, Menter A. Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the Cancer Research Network experience. J Thorac Oncol. 2014 2014 May;9(5):692-701. doi: 10.1097/JTO.0000000000000127. PubMed
Aiello Bowles EJ, Wernli KJ, Gray HJ, Bogart A, Delate T, O’Keefe-Rosetti M, Nekhylyudov L, Trice Loggers E. Diffusion of intraperitoneal chemotherapy in women with advanced ovarian cancer in community settings 2003-2008: the effect of the NCI clinical recommendation. Front Oncol. 2014 Mar 10;4:43. doi: 10.3389/fonc.2014.00043. eCollection 2014. PubMed
Loggers ET, Prigerson HG. The end-of-life experience of patients with rare cancers and their caregivers. Rare Tumors. 2014 Mar 24;6(1):5281. doi: 10.4081/rt.2014.5281. eCollection 2014. PubMed
Zeliadt SB, Loggers ET, Slatore CG, Au DH, Hebert PL, Klein GJ, Kessler LG, Backhus LM. Preoperative PET and the reduction of unnecessary surgery among newly diagnosed lung cancer patients in a community setting. J Nucl Med. 2014 Jan 21. [Epub ahead of print]. PubMed
Delate T, Won K, Carroll NM, Kushi L, Hornbrook M, Aiello Bowles EJ, Menter A, Loggers ET, Ritzwoller D. Factors associated with first-line bevacizumab use in advanced, non-squamous, non-small cell lung cancer. J Cancer Res Ther. 2014;2(1):1-8.
Henrikson N, Tuzzio L, Loggers ET, Miyoshi J, Buist DS. Patient and oncologist discussions about cancer care costs. Support Care Cancer. 2013 Nov 26. [Epub ahead of print]. PubMed
Loggers ET, Maciejewski PK, Jimenez R, Nilsson M, Paulk E, Stieglitz H, Prigerson HG. Predictors of intensive end-of-life and hospice care in Latino and white advanced cancer patients. J Palliat Med. 2013 Oct;16(10):1249-54. doi: 10.1089/jpm.2013.0164. Epub 2013 Sep 20. PubMed
Ritzwoller DP, Carroll N, Delate T, O'Keeffe-Rossetti M, Fishman PA, Loggers ET, Aiello Bowles EJ, Elston-Lafata J, Hornbrook MC. Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care. 2013 Oct;51(10):e67-73. doi: 10.1097/MLR.0b013e31824def85. Epub 2012 Apr 23. PubMed
Chang AE, Mann GN, Hoch B, Loggers ET, Pollack SM, Kolokythas O, Jones RL. Multiple liver abscess formation and primary gastrointestinal stromal tumor. Rare Tumors. 2013 Sep 4;5(3):e51. doi: 10.4081/rt.2013.e51. PubMedTo view more publications, please see Dr. Logger’s CV.